CD8A and neoplasm: In support of the latter, recent studies revealed that migratory cDC1 transfer tumour antigens and PRR‐agonists to CD8α+ res‐cDC1 through direct physical interactions in the tdLN, enabling them to participate in anti‐tumour CD8+ T cell priming [79, 80].